Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with reduced tacrolimus and early steroid withdrawal versus standard tacrolimus, mycophenolate mofetil, and steroids in pediatric kidney transplant recipients
2010-024381-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute rejection (AR) comparing Everolimus + reduced tacrolimus + early steroid elimination with Standard tacrolimus + mycophenolate mofetil + steroids (2 arms). Primary endpoint: Incidence of composite efficacy failure at 12 months. Started Jul 2011; status: completed.
02
Drugs
everolimustacrolimusmycophenolate mofetil
03
Conditions
acute rejection (AR)
Beyond the preview
Go deeper on 2010-024381-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024381-21.